Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Cited by (1,026)

Items 401–500 of 1,026

1. Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold
   Vredevoogd, David W., Kuilman, Thomas, Ligtenberg, Maarten A., Boshuizen, Julia, Stecker, Kelly E., de Bruijn, Beaunelle, Krijgsman, Oscar, Huang, Xinyao, Kenski, Juliana C.N., Lacroix, Ruben et al. · 2019 · Cell
2. Novel immunotherapies in lymphoid malignancies
   Connie Lee Batlevi, Eri Matsuki, Renier J. Brentjens, Anas Younes · 2015 · Nature Reviews Clinical Oncology
3. PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy
   Xinyi Tu, Bo Qin, Yong Zhang, Cheng Zhang, Mohamed M.H. Kahila, Somaira Nowsheen, Ping Yin, Jian Yuan, Huadong Pei, Hu Li et al. · 2019 · Molecular Cell
4. Checkpoint inhibitor immunotherapy in kidney cancer
   Wenxin Vincent Xu, Michael B. Atkins, David F. McDermott · 2020 · Nature Reviews Urology
5. Emerging Tim-3 functions in antimicrobial and tumor immunity
   Kaori Sakuishi, Pushpa Jayaraman, Samuel M. Behar, Ana Carrizosa Anderson, Vijay Kumar Kuchroo · 2011 · Trends in Immunology
6. Programmed Death (PD)-1:PD-Ligand 1/PD-Ligand 2 Pathway Inhibits T Cell Effector Functions during Human Tuberculosis
   Javier O. Jurado, Ivana B. Alvarez, Virginia Pasquinelli, Gustavo Martínez, María Florencia Quiroga, Eduardo H Abbate, Rosa María Musella, Eduardo Chuluyán, Verónica García · 2008 · The Journal of Immunology
7. Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma
   Geoffrey Thomas Gibney, Ragini Reiney Kudchadkar, Ronald C. DeConti, Melissa S. Thebeau, Maria P. Czupryn, Leticia F. Tetteh, Cabell E. Eysmans, Allison D. Richards, Michael J. Schell, Kate J. Fisher et al. · 2014 · Clinical Cancer Research
8. Effector, Memory, and Dysfunctional CD8+T Cell Fates in the Antitumor Immune Response
   John Reiser, Arnob Banerjee · 2016 · Journal of Immunology Research
9. Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non–Small-Cell Lung Cancer: A Review
   Sacher, Adrian G., Gandhi, Leena · 2016 · JAMA Oncology
10. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients
    Marius Ilié, Véronique Hofman, Manfred Dietel, Jean‐Charles Soria, Paul M Hofman · 2016 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
11. Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer
    Huimin Zhang, Chunhong Qin, Changming An, Xiwang Zheng, Shuxin Wen, Wenjie Chen, Xianfang Liu, Zhenghua Lv, Ping–Chang Yang, Wei Xu et al. · 2021 · Molecular Cancer
12. The Biology of Human Lymphoid Malignancies Revealed by Gene Expression Profiling
    Louis M. Staudt, Sandeep S. Davé · 2005 · Advances in immunology
13. Biomarkers for immunotherapy response in head and neck cancer
    Niki Gavrielatou, S Doumas, Panagiota Economopoulou, Periklis G. Foukas, Amanda Psyrri · 2020 · Cancer Treatment Reviews
14. Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559)*
    Richard S. Hotchkiss, Elizabeth Colston, Sachin P. Yende, Derek C. Angus, Lyle L. Moldawer, Elliott D. Crouser, Greg S. Martin, Craig M. Coopersmith, Scott C. Brakenridge, Florian Mayr et al. · 2019 · Critical Care Medicine
15. Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy
    Lee, Nayoung, Zakka, Labib R., Mihm, Martin C., Schatton, Tobias · 2016 · Pathology
16. Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma
    Rezaul Karim, Ekaterina S. Jordanova, Sytse J. Piersma, Gemma G. Kenter, Lieping Chen, Judith M. Boer, Cornelis J.M. Melief, Sjoerd H. van der Burg · 2009 · Clinical Cancer Research
17. Clinical cancer immunotherapy: Current progress and prospects
    Chenglong Liu, Mengxuan Yang, Daizhou Zhang, Ming Chen, Di Zhu · 2022 · Frontiers in Immunology
18. Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
    Janis Marie Taube, Geoffrey D. Young, Tracee L. McMiller, Shuming Chen, January T. Salas, Theresa S. Pritchard, Haiying Xu, Alan Keith Meeker, Jinshui Fan, Chris Cheadle et al. · 2015 · Clinical Cancer Research
19. Cardiotoxicity of immune checkpoint inhibitors
    Gilda Varricchi, Maria Rosaria Galdiero, Giancarlo Marone, Gjada Criscuolo, Maria Triassi, Domenico Bonaduce, Gianni Marone, Carlo Gabriele Tocchetti · 2017 · ESMO Open
20. Phenotype, Function, and Gene Expression Profiles of Programmed Death-1hi CD8 T Cells in Healthy Human Adults
    Jaikumar Duraiswamy, Chris Ibegbu, David Masopust, Joseph D Miller, Koichi Araki, Gregory Doho, Pramila Tata, Gupta Sk, Michael J. Zilliox, Helder Imoto Nakaya et al. · 2011 · The Journal of Immunology
21. Immunocompetent murine models for the study of glioblastoma immunotherapy
    Taemin Oh, Shayan Fakurnejad, Eli T. Sayegh, Allan Clark, Michael E. Ivan, Matthew Z. Sun, Michael Safaee, Orin G. Bloch, Charles David James, Andrew T. Parsa · 2014 · Journal of Translational Medicine
22. Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis
    Hui Zhang, Ryu Watanabe, Gerald J. Berry, Augusto Vaglio, Yaping Joyce Liao, Kenneth J. Warrington, Jörg J. Goronzy, Cornelia M. Weyand · 2017 · Proceedings of the National Academy of Sciences
23. Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma
    Duaa O. Khair, Heather J. Bax, Silvia Mele, Silvia Crescioli, Giulia Pellizzari, Atousa Khiabany, Mano Nakamura, R. J. C. Harris, Elise French, Ricarda M. Hoffmann et al. · 2019 · Frontiers in Immunology
24. Checkpoint blocking antibodies in cancer immunotherapy
    Chrisann Kyi, Michael A. Postow · 2013 · FEBS Letters
25. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy
    Chong-xian Pan, Hongtao Liu, Elizabeth Robins, Wenru Song, Delong Liu, Zihai Li, Lei Zheng · 2020 · Journal of Hematology & Oncology
26. Assessing the interactions between radiotherapy and antitumour immunity
    Grassberger, Clemens, Ellsworth, Susannah G., Wilks, Moses Q., Keane, Florence K., Loeffler, Jay S. · 2019 · Nature Reviews Clinical Oncology
27. Genomic Organization and Expression Analysis of B7-H4, an Immune Inhibitory Molecule of the B7 Family
    In-Hak Choi, Gefeng Zhu, Gabriel Sica, Scott Eric Strome, John C. Cheville, Julie S. Lau, Yuwen Zhu, Dallas B. Flies, Koji Tamada, Lieping Chen · 2003 · The Journal of Immunology
28. The Transcription Factor Bhlhe40 Programs Mitochondrial Regulation of Resident CD8+ T Cell Fitness and Functionality
    Chaofan Li, Bibo Zhu, Young Min Son, Zheng Wang, Li Jiang, Min Xiang, Zhenqing Ye, Kathryn Eby Beckermann, Yue Wu, James W. Jenkins et al. · 2019 · Immunity
29. The Extrinsic and Intrinsic Roles of PD‐L1 and Its Receptor PD‐1: Implications for Immunotherapy Treatment
    Hudson, Katie, Cross, Neil, Jordan-Mahy, Nicola, Leyland, Rebecca · 2020 · Frontiers in Immunology
30. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer
    Yan Zhang, Shengdong Huang, Dejun Gong, Yanghua Qin, Qian Shen · 2010 · Cellular and Molecular Immunology
31. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma
    Young‐Ah Cho, Hye‐Jung Yoon, Jae‐Il Lee, Sam‐Pyo Hong, Seong‐Doo Hong · 2011 · Oral Oncology
32. PD-1 Regulates Self-Reactive CD8+ T Cell Responses to Antigen in Lymph Nodes and Tissues
    Mary E Keir, Gordon James Freeman, Arlene H. Sharpe · 2007 · The Journal of Immunology
33. Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines
    Yongjing Chen, Qin Wang, Bimin Shi, Ping Xu, Zhenhua Hu, Li-xiong Bai, Xueguang Zhang · 2011 · Cytokine
34. Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties
    Jennifer C. Rodrigues, Guido C. Gonzalez, Lei Zhang, George M. Ibrahim, John J. Kelly, Michael P. Gustafson, Yi Lin, Allan B. Dietz, Peter A. Forsyth, Voon Wee Yong et al. · 2009 · Neuro-Oncology
35. Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy
    Stephen J. Blake, Kimberley A. Stannard, Jing Liu, Stacey M. Allen, Michelle C.R. Yong, Deepak Mittal, Amelia Roman Aguilera, John J. Miles, Viviana P. Lutzky, Lucas Ferrari de Andrade et al. · 2016 · Cancer Discovery
36. YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma
    Kim, Min Hwan, Kim, Chang Gon, Kim, Sang-Kyum, Shin, Sang Joon, Choe, Eun Ah, Park, Su-Hyung, Shin, Eui-Cheol, Kim, Joon · 2018 · Cancer Immunology Research
37. Combinations of Immunotherapy and Radiation in Cancer Therapy
    Ralph E. Vatner, Benjamin Thomas Cooper, Claire Vanpouille‐Box, Sandra Demaria, Silvia Chiara Formenti · 2014 · Frontiers in Oncology
38. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects
    Hongyan Jia, Cristina I. Truica, Bin Wang, Yanhong Wang, Xingcong Ren, Harold A. Harvey, Jianxun Jim Song, Jinming Yang · 2017 · Drug Resistance Updates
39. Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment
    Guangna Liu, Wei Rui, Xueqiang Zhao, Xin Lin · 2021 · Cellular and Molecular Immunology
40. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma
    Reid W. Merryman, Haesook T. Kim, Pier Luigi Zinzani, Carmelo Carlo‐Stella, Stephen Maxted Ansell, Miguel-Angel Perales, Abraham Avigdor, Ahmad Sami Halwani, Roch Houot, Tony Marchand et al. · 2017 · Blood
41. Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens
    Papalexi, Efthymia, Mimitou, Eleni P., Butler, Andrew W., Foster, Samantha, Bracken, Bernadette, Mauck, William M., Wessels, Hans-Hermann, Hao, Yuhan, Yeung, Bertrand Z., Smibert, Peter et al. · 2021 · Nature Genetics
42. Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens
    Richard W. Childs, Mattias Carlsten · 2015 · Nature Reviews Drug Discovery
43. The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck
    Dan Paul Zandberg, Scott Eric Strome · 2014 · Oral Oncology
44. OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
    Stefanie N. Linch, Michael J. McNamara, William L. Redmond · 2015 · Frontiers in Oncology
45. Immune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms
    Moslehi, Javid, Lichtman, Andrew H., Sharpe, Arlene H., Galluzzi, Lorenzo, Kitsis, Richard N. · 2021 · Journal of Clinical Investigation
46. Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy
    Fumihiko Tsushima, Sheng Yao, Tahiro Shin, Andrew S. Flies, Sarah J. Flies, Haiying Xu, Koji Tamada, Drew M. Pardoll, Lieping Chen · 2007 · Blood
47. B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis
    Aaron Scott Mansfield, Anja Christiane Roden, Tobias Peikert, Yuri M. Sheinin, Susan M. Harrington, Christopher J. Krco, Haidong Dong, Eugene D. Kwon · 2014 · Journal of Thoracic Oncology
48. Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non–Small Cell Lung Cancer
    Valsamo Anagnostou, Julie Renee Brahmer · 2015 · Clinical Cancer Research
49. Multiple Targets of the Canonical WNT/β-Catenin Signaling in Cancers
    Yves Lecarpentier, Olivier Schussler, Jean‐Louis Hébert, Alexandre Vallée · 2019 · Frontiers in Oncology
50. Exploiting innate immunity for cancer immunotherapy
    Ming Yi, Tianye Li, Mengke Niu, Qi Mei, Bin Zhao, Qian Chu, Zhijun Dai, Kongming Wu · 2023 · Molecular Cancer
51. Clinical development of targeted and immune based anti-cancer therapies
    Nicole A. Seebacher, Alexandra E. Stacy, Georgia Porter, Angelica M. Merlot · 2019 · Journal of Experimental & Clinical Cancer Research
52. Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti–PD-L1 Antibodies
    Sandra Heskamp, Willemijn A. Hobo, Janneke D.M. Molkenboer‐Kuenen, Daniel Olive, Wim J.G. Oyen, Harry Dolstra, Otto C. Boerman · 2015 · Cancer Research
53. Aberrant Regulation of Synovial T Cell Activation by Soluble Costimulatory Molecules in Rheumatoid Arthritis
    Bing Wan, Hong Nie, Ailian Liu, Guozhang Feng, Dongyi He, Rong Xu, Qi Zhang, Chen Dong, Jingwu Z. Zhang · 2006 · The Journal of Immunology
54. Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule
    Hazem Ghebeh, Cynthia L. Lehé, Eman Barhoush, Khaldoun I. Al-Romaih, Asma M. Tulbah, Monther M Al-Alwan, Siti‐Faujiah Hendrayani, Pulicat Subramanian Manogaran, Ayodele A. Alaiya, Taher Al‐Tweigeri et al. · 2010 · Breast Cancer Research
55. The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer
    Heidrun Gevensleben, Dimo Dietrich, Carsten Golletz, Susanne Steiner, Maria Jung, Thore Thiesler, Michael Majores, Johannes Stein, Barbara Uhl, Stefan Müller et al. · 2015 · Clinical Cancer Research
56. The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells
    Chunwan Lu, Priscilla S. Redd, Jeffrey R. Lee, Natasha M. Savage, Kebin Liu · 2016 · OncoImmunology
57. High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma
    Yueh-Min Lin, Wen‐Wei Sung, Ming‐Ju Hsieh, Shih-Chen Tsai, Hung‐Wen Lai, Shu-Mei Yang, Ko-Hong Shen, Mu-Kuan Chen, Huei Lee, Kun-Tu Yeh et al. · 2015 · PLoS ONE
58. PD-1:PD-L1 Interactions Contribute to the Functional Suppression of Virus-Specific CD8+ T Lymphocytes in the Liver
    Holly Maier, Masanori Isogawa, Gordon James Freeman, Francis V. Chisari · 2007 · The Journal of Immunology
59. High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection
    Tong Ding, Jing Xu, Fang Wang, Ming Shi, Ying Zhang, Shengping Li, Limin Zheng · 2008 · Human Pathology
60. A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection
    David Gardiner, Jacob Paul Lalezari, Eric Lawitz, Michael DiMicco, Rheem Ghalib, K. Rajender Reddy, Kyong‐Mi Chang, Mark Sulkowski, Steven O’ Marro, Jeffrey Anderson et al. · 2013 · PLoS ONE
61. Selection of CD8+PD-1+ Lymphocytes in Fresh Human Melanomas Enriches for Tumor-reactive T Cells
    Takashi Inozume, Ken‐ichi Hanada, Qiong J. Wang, Mojgan Ahmadzadeh, John R. Wunderlich, Steven A. Rosenberg, James Chih-Hsin Yang · 2010 · Journal of Immunotherapy
62. Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology
    Mark Selby, John Engelhardt, Robert J. Johnston, Li-Sheng Lu, Minhua Han, Kent B. Thudium, Dapeng Yao, Michael M. Quigley, Jose Valle, Changyu Wang et al. · 2016 · PLoS ONE
63. Overcoming Immune Evasion in Melanoma
    Kevinn Eddy, Suzie Chen · 2020 · International Journal of Molecular Sciences
64. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs
    R. M. S. Wong, Ronaldo Scotland, Roy Lau, Chenhui Wang, Alan J. Korman, W. Martin Kast, Jeffrey S. Weber · 2007 · International Immunology
65. Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
    Fei Zhang, Hudie Wei, Xiaoxiao Wang, Yu Bai, Pilin Wang, Jiawei Wu, Xiaoyong Jiang, Yugang Wang, Haiyan Cai, Ting Xu et al. · 2017 · Cell Discovery
66. Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy
    Jinfang Zhang, Fabin Dang, Junming Ren, Wenyi Wei · 2018 · Trends in Biochemical Sciences
67. Targeting immune cells for cancer therapy
    Sin Yee Gun, Sharon Wei Ling Lee, Je Lin Sieow, Siew Cheng Wong · 2019 · Redox Biology
68. The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity
    Suzanne Ostrand‐Rosenberg, Lucas A. Horn, Samuel T. Haile · 2014 · The Journal of Immunology
69. Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment
    Diego Omar Croci, Mariano F. Zacarías Fluck, María José Rico, Pablo Matar, Gabriel A. Rabinovich, Olga Graciela Scharovsky · 2007 · Cancer Immunology Immunotherapy
70. Nivolumab in NSCLC: latest evidence and clinical potential
    Raghav Sundar, Byoung Chul Cho, Julie Renee Brahmer, Ross Andrew Soo · 2015 · Therapeutic Advances in Medical Oncology
71. The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer
    Jeffrey P. Ward, Matthew M. Gubin, Robert D. Schreiber · 2016 · Advances in immunology
72. Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB
    Kavitha Gowrishankar, Dilini Gunatilake, Stuart J. Gallagher, Jessamy C. Tiffen, Helen Rizos, Peter Hersey · 2015 · PLoS ONE
73. Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy
    Yanping Xu, Lei Lv, Ying Liu, Matthew D. Smith, Wencai Li, Xianming M. Tan, Meng Cheng, Zhijun Li, Michael Bovino, Jeffrey Aubé et al. · 2019 · Journal of Clinical Investigation
74. D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1
    Ruonan Zhang, Yajing Yang, Wenjing Dong, Mingen Lin, Jing He, Xinchao Zhang, Tongguan Tian, Yunlong Yang, Kun Chen, Qun‐Ying Lei et al. · 2022 · Proceedings of the National Academy of Sciences
75. New regulatory co-receptors: inducible co-stimulator and PD-1
    Taku Okazaki, Yoshiko Iwai, Tasuku Honjo · 2002 · Current Opinion in Immunology
76. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma
    Hideto Tamura, Mariko Ishibashi, Takashi Yamashita, Sakae Tanosaki, Namiko Okuyama, Asaka Kondo, Hideya Hyodo, Eiji Shinya, Hidemi Takahashi, Haidong Dong et al. · 2012 · Leukemia
77. Implications of B7-H1 Expression in Clear Cell Carcinoma of the Kidney for Prognostication and Therapy
    Robert Houston Thompson, Haidong Dong, Eugene D. Kwon · 2007 · Clinical Cancer Research
78. RETRACTED ARTICLE: Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cells
    Yuying Liu, Xiaoyu Liang, Xiaonan Yin, Jiadi Lv, Ke Tang, Jingwei Ma, Tiantian Ji, Huafeng Zhang, Wenqian Dong, Xun Jin et al. · 2017 · Nature Communications · Retracted
79. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G
    Edgardo Delfino Carosella, Guillaume Ploussard, Joël LeMaoult, François Desgrandchamps · 2015 · European Urology
80. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study
    Jonathan Strosberg, Nobumasa Mizuno, Toshihiko Doi, Enrique Grande, Jean‐Pierre Delord, Ronnie Shapira‐Frommer, Emily K. Bergsland, Manisha H. Shah, Marwan Fakih, Shunji Takahashi et al. · 2020 · Clinical Cancer Research
81. A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
    Robert D. Leone, Ying-Chun Lo, Jonathan D. Powell · 2015 · Computational and Structural Biotechnology Journal
82. Current Status and Future Directions
    Fumito Ito, Alfred E. Chang · 2013
83. Overall survival and PD‐L1 expression in metastasized malignant melanoma
    Jules Gadiot, Anna I. Hooijkaas, Andrew Kaiser, Harm van Tinteren, Hester van Boven, Christian Blank · 2010 · Cancer
84. PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction
    Kaoru Abiko, Masaki Mandai, Junzo Hamanishi, Yumiko Yoshioka, Noriomi Matsumura, Tsukasa Baba, Ken D Yamaguchi, Ryusuke Murakami, Ayaka Yamamoto, Budiman Kharma et al. · 2013 · Clinical Cancer Research
85. Clinical Significance of Programmed Death-1 Ligand-1 Expression in Patients with Non-Small Cell Lung Cancer: A 5-year-follow-up Study
    Yanbin Chen, Chuanyong Mu, Jian‐An Huang · 2012 · Tumori Journal
86. Targeted xCT‐mediated Ferroptosis and Protumoral Polarization of Macrophages Is Effective against HCC and Enhances the Efficacy of the Anti‐PD‐1/L1 Response
    Bufu Tang, Jinyu Zhu, Yajie Wang, Weiqian Chen, Shiji Fang, Weiyang Mao, Ziwei Xu, Yang Yang, Qiaoyou Weng, Zhongwei Zhao et al. · 2022 · Advanced Science
87. CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell–Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1
    Yunqin Lee, June Ho Shin, Michelle R. Longmire, Hua Wang, Holbrook E K Kohrt, Howard Y. Chang, John B. Sunwoo · 2016 · Clinical Cancer Research
88. Armed Oncolytic Adenovirus–Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors
    Kiyonori Tanoue, Amanda Rosewell Shaw, Norihiro Watanabe, Caroline Porter, Bhakti Rana, Stephen M Gottschalk, Malcolm K. Brenner, Masataka Suzuki · 2017 · Cancer Research
89. PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review
    Gabrielle Planes-Laine, Philippe Rochigneux, François Bertucci, Anne-Sophie Chrétien, Patrice Viens, Renaud Sabatier, Anthony Gonçalvès · 2019 · Cancers
90. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders
    Ryan A. Wilcox, Andrew L. Feldman, David A. Wada, Zhi‐Zhang Yang, Nneka I. Comfere, Haidong Dong, Eugene D. Kwon, Anne Josephine Novak, Svetomir N. Markovic, Mark R. Pittelkow et al. · 2009 · Blood
91. Glioma-Associated Cancer-Initiating Cells Induce Immunosuppression
    Jun Wei, Jason Barr, Ling-Yuan Kong, Yongtao Wang, Adam Wu, Amit Kumar Sharma, Joy Gumin, Verlene K. Henry, Howard Colman, Raymond A. Sawaya et al. · 2010 · Clinical Cancer Research · Retracted
92. Mechanisms of immune evasion in bladder cancer
    Paul L. Crispen, Sergei A. Kusmartsev · 2019 · Cancer Immunology Immunotherapy
93. MicroRNA-513 Regulates B7-H1 Translation and Is Involved in IFN-γ-Induced B7-H1 Expression in Cholangiocytes
    Ai‐Yu Gong, Rui Zhou, Guoku Hu, Xiaoqing Li, Patrick L. Splinter, Steven P. O’Hara, Nicholas F. LaRusso, Garrett A. Soukup, Haidong Dong, Xian‐Ming Chen · 2009 · The Journal of Immunology
94. LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint
    Lina Zhao, Ye Liu, Jingbo Zhang, Yan Liu, Qi Qi · 2019 · Cell Death and Disease
95. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation
    Susana Salceda, Tenny Tang, Muriel Kmet, Andrei Ioan Munteanu, Malavika Ghosh, Roberto A. Macina, Wenhui Liu, Glenn R. Pilkington, Jackie Papkoff · 2005 · Experimental Cell Research
96. Autophagy in cancer development, immune evasion, and drug resistance
    Xuegang Niu, Qi You, Kaijian Hou, Yu Tian, Penghui Wei, Yang Zhu, Bin Gao, Milad Ashrafizadeh, Amir Reza Aref, Alireza Kalbasi et al. · 2024 · Drug Resistance Updates
97. Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway
    Shen, Mingjing, Xu, Zhonghua, Xu, Weihua, Jiang, Kanqiu, Zhang, Fuquan, Ding, Qifeng, Xu, Zhonghen, Chen, Yongbing · 2019 · Journal of Experimental & Clinical Cancer Research
98. The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy
    Wang, Gui-Zhen, Zhang, Li, Zhao, Xin-Chun, Gao, San-Hui, Qu, Li-Wei, Yu, Hong, Fang, Wen-Feng, Zhou, Yong-Chun, Liang, Fan, Zhang, Chen et al. · 2019 · Nature Communications
99. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma
    Yang Zhang, Lei Wang, Yuan Li, Yunjian Pan, Haichuan Hu, Hang Li, Xiaoyang Luo, Ting Ye, yihua sun, haiquan chen et al. · 2014 · OncoTargets and Therapy
100. Melanoma subtypes demonstrate distinct PD-L1 expression profiles
     Genevieve J. Kaunitz, Tricia R. Cottrell, Mohammed T. Lilo, Valliammai Muthappan, Jessica Esandrio, Sneha Berry, Haiying Xu, Aleksandra Ogurtsova, Robert A. Anders, Alexander H. Fischer et al. · 2017 · Laboratory Investigation